-
CGRP-targeted migraine drug head-to-head study Eli Lilly launches Phase IV clinical trial of Emgality
Time of Update: 2021-06-22
On Tuesday, the company announced that in order to advance the science of migraine treatment and help understand the role of CGRP monoclonal antibodies (mAbs) and oral CGRP receptor antagonists in preventing migraines, it will conduct a head-to-head study.
-
How should the drug manufacturer on the docking list receive drug inspections
Time of Update: 2021-06-08
2. Refuse and evade supervision and inspectionIf there is evidence that a drug manufacturer may have a potential safety hazard, the drug supervision and administration department shall, based on the supervision and inspection situation, take measures such as warnings, interviews, rectification within a time limit, and suspension of production, sales, use, and import, and promptly announce the inspection and handling results.
-
TP53 Mutant Bone Marrow Growth Abnormal Syndrome: Eprenetapopt did not reach the main endpoint of the Phase III study
Time of Update: 2021-01-15
A Phase III study of patients with TP53 mutant bone marrow growth syndrome has failed to reach the primary endpoint of its total remission (CR) rate, pharmaceutical company Aprea Therapeutics said recently.
but the eprenetapopt joint Aza cytosine group showed good tolerance, and the adverse event characteristics were similar to those of the Phase II trial.
-
Clin Cancer Res: A combination of drug therapies is effective in treating melanoma
Time of Update: 2020-12-19
lead author Amanda Truong of HCI McMahon Labs explains that genetic variants of GNAQ and GNA11 are often found in patients with vine melanoma, the main targets of these drugs.
-
Redsyvir will become the first COVID-19 drug to go into space for research
Time of Update: 2020-12-11
InnoStudio, one of the experiment's customers, said in a statement in November that the team behind Redsivir's study on the International Space Station hopes it will make the drug more effective and reduce the risk of kidney problems in patients with kidney problems.
-
Weekend Talk: Accelerated approval and slow withdrawal
Time of Update: 2020-10-31
month, the FDA offered to revoke the accelerated approval of AMAG's prematric progesterone drug Makena because a corrogical trial failed.
-
Pfizer's new antifellar drug, Aishaconazole, has been declared on the market in China
Time of Update: 2020-10-21
On July 4, Pfizer filed a CDE application in China for the listing of Essaconazole sulphuric acid capsules and injection aesulphate.
, a new antifellar drug developed by Basilea Pharmaceutica, was approved by the FDA in March 2015 under the name Crisemba.
-
Colum Pharmaceuticals' "橼 Acid Sidna non-mouth collapse tablets" was the first domestic newspaper to go on sale
Time of Update: 2020-10-14
Insight database shows that there are currently few domestic companies layout of West Dina non-mouth-breaking tablets, Dr. Reddy of India in 2017 to submit a generic drug market application in China, 2018 shows that the batch is not expected to be approved.
-
Health insurance catalog adjustment list public! 751 varieties passed the formal review
Time of Update: 2020-10-09
Condition 6: Between January 1, 2015 and August 17, 2020, according to the results of clinical trials, the State Drug Administration to supplement the application and obtain approval, adaptation, functional treatment and other significant changes in the drug.
-
Peak Loop-To Microbiome Innovation Therapy reaches critical Phase 3 clinical endpoint
Time of Update: 2020-09-16
FDA has granted SER-109 breakthrough therapy and orphan drug qualification for treatment of CDI.
in the SER-109 trial, 182 patients with multiple CDI were treated with SER-109 or a placebo, and all were treated with standard antibiotics.
-
The health insurance bureau news that the repayment policy is coming
Time of Update: 2020-09-08
On August 17th, Henan Provincial Health Insurance Bureau issued the Implementation Plan for the Centralized Procurement and Use of Pharmaceutical Medical Supplies in Henan Province, which states that the prices of pharmaceutical supplies in our province will be further reduced; implementation, the scope of procurement will be gradually expanded, in accordance with the "provincial organizations, alliance procurement, platform operations" of the overall thinking, to ensure quality, ensure supply, ensure use, ensure repayment.
-
The $2.2 billion heavyweight variety will be taken down first
Time of Update: 2020-09-04
Pharmaceutical Network August 13th, August 7th, the first sound pharmaceutical industry according to the imitation of 4 categories of reported acid tofatic cloth tablets (acceptance number CYHS1900544) for the status of change to "in approval", is expected to be approved in recent days and treated as a review.
-
750 million! Two well-known pharmaceutical companies were sold
Time of Update: 2020-08-19
affected by Sino-US trade friction, the new crown pneumonia outbreak and other adverse factors, the company's peptide business, in vitro diagnostic reagents business are facing development bottlenecks, Kangyong Bio 2019 and sino-peptide biochemical 2020 first quarter have a loss.
-
Huazhong Agricultural University genetically modified rice Huahui No. 1 through the FDA safety evaluation
Time of Update: 2020-08-14
According to the relevant person in charge of Huazhong Agricultural University, genetically modified insect-resistant rice "Huahui 1" passed the FDA and ENVIRONMENTAL Protection Agency safety review procedures, meaning that "Huahui 1" rice and its products can be exported to the United States and into its market for direct sales to ordinary consumers.
-
Immunosuppressants or new anchors for band-buying competitive landscape sit back
Time of Update: 2020-08-02
so, for immunosuppressants such a large number of head varieties, fierce competition, and patients need long-term drug use of the large market, belt procurement will bring what kind of game to promote market restructuring?
